Book a Consultation
(480) 841-9279
Book a Consultation

FDA-Cleared TMS Therapy
in Scottsdale, AZ

Timeline and Key Studies

TMS FDA-Cleared

2008

FDA-Cleared for Treatment-Resistant Depression

The first FDA-Cleared for TMS came in 2008. This landmark decision followed rigorous studies that demonstrated TMS’s effectiveness and safety for adults with major depressive disorder who had not responded to at least one antidepressant medication.

Key Study: O'Reardon et al., 2007

In a randomized, controlled trial published in Biological Psychiatry, researchers found that patients treated with TMS experienced significantly greater improvement in depression symptoms compared to those receiving a placebo. This study was foundational in the FDA’s decision to approve TMS for depression, as it demonstrated both safety and efficacy with a high response rate in patients who had previously found no relief with medication.
  • FDA Decision: October 2008 — The FDA authorized the use of TMS for adult patients with TRD based on evidence showing TMS was safe and well-tolerated, with benefits that extended beyond the treatment period.

2013

FDA Expands TMS Indications to Include Additional Devices

Following TMS’s initial approval, the FDA evaluated additional devices and approved new TMS systems, including Brainsway’s Deep TMS device, which allows for a broader and deeper magnetic field penetration into the brain, targeting additional areas linked to depression.

Key Study: Levkovitz et al., 2015

This study, published in The World Journal of Biological Psychiatry, tested Deep TMS’s impact on patients with depression and confirmed that the new system was safe and effective. Deep TMS showed promising results, with many patients experiencing a rapid reduction in symptoms, which contributed to its FDA-Cleared.
  • FDA Decision: January 2013 — The FDA Cleared Brainsway's Deep TMS system for MDD, expanding treatment options for patients and introducing a new device that could target brain regions more effectively.

2018

FDA-Cleared for TMS in Treating Obsessive-Compulsive Disorder (OCD)

As research continued to support TMS’s benefits beyond depression, the FDA-Cleared TMS for obsessive-compulsive disorder (OCD) in 2018, marking it as the first non-invasive neuromodulation treatment for OCD.

Key Study: Carmi et al., 2019

Published in The American Journal of Psychiatry, this study evaluated the effects of Deep TMS on patients with OCD, showing a significant reduction in symptom severity after treatment. Patients treated with TMS experienced improvements that were maintained over time, supporting TMS’s efficacy for OCD.
  • FDA Decision: August 2018 — This approval expanded TMS's use, providing a new treatment option for individuals with OCD who had not found relief from traditional therapies.

2021

TMS Approval for Smoking Cessation

TMS gained FDA cleared for smoking cessation in 2021, broadening its therapeutic applications beyond mental health to include addiction.

Key Study: Dinur-Klein et al., 2014

This early study, published in Biological Psychiatry, demonstrated TMS’s effectiveness in reducing cigarette cravings and consumption in smokers. Patients undergoing TMS therapy were able to maintain reduced smoking rates, and the findings contributed to TMS’s approval as a tool for smoking cessation.
  • FDA Decision: August 2021 — The FDA cleared TMS as a smoking cessation aid, allowing it to be offered as a treatment for individuals seeking help in quitting smoking, marking another significant milestone in TMS's medical applications.

Why Choose FDA-Cleared TMS Therapy?

With each FDA cleared, TMS has proven itself to be not only a safe and effective treatment for various conditions but also a therapy backed by rigorous research and real-world results.

Safety and Reliability

  • Every FDA cleared requires strict testing and evidence of safety and efficacy. TMS has consistently met these standards, providing patients with peace of mind.

Non-Invasive and Minimal Side Effects

  • Unlike medications, TMS does not cause systemic side effects, making it a great option for those who are sensitive to or unable to take antidepressants. Side effects are generally mild and temporary, including possible headaches or scalp discomfort.

Effective for Treatment-Resistant Conditions

  • TMS is especially beneficial for people with treatment-resistant depression and OCD. Studies show that TMS can achieve significant symptom relief, even when other treatments have failed.

Ongoing Research and Expanding Approvals

  • The FDA continues to review and approve new applications for TMS, showing that its benefits may extend even further. Patients can expect TMS technology to advance as research uncovers new ways it can support mental health and wellness.

Frequently Asked Questions

Is TMS covered by insurance?
Yes, most insurance companies cover TMS for depression, particularly for individuals who have tried multiple antidepressants without success. Coverage varies by provider and condition, so check with your insurance for specific details.
A typical TMS session lasts around 20-40 minutes. Treatment usually involves daily sessions for several weeks, depending on the individual’s treatment plan.
TMS is generally well-tolerated, with few side effects. Some patients may experience mild headaches or scalp discomfort, but these usually subside after the first few sessions. Serious side effects are extremely rare.
Candidates for TMS therapy include those with major depressive disorder who have not responded to at least one antidepressant. Individuals with OCD or who are looking to quit smoking may also qualify.
  • If you or someone you know is in crisis, call or text 988 to reach the Suicide & Crisis Lifeline.

Start Your Journey with FDA-Cleared TMS Therapy Today

If you or someone you know is seeking an alternative to traditional treatments for depression or OCD , TMS may be the solution. With FDA cleared spanning over a decade and supported by rigorous studies, TMS offers a promising future in mental health treatment.

Contact Us
Call Now: (480) 841-9279
(480) 841-9279